Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Beijing Second Pharma Wins US Approval for Anti- Hypertensive

publication date: May 3, 2011
Beijing Second Pharmaceutical Co. was granted FDA approval for US use of Amlodipine Besylate, a long-acting calcium channel blocker that is prescribed for hypertension and angina. The drug is a generic version of Pfizer’s Norvasc®. According to the company, the approval is the first time the FDA has approved an oral, solid-dose product from a China-owned pharma. BSPC will market the product through a US-based distribution partner. More details....

Stock Symbol: (NYSE: PFE)     Share this with colleagues:  


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here